Home    Back

 333. Hutchinson-Gilford syndrome
 [ 5 clinical trials,    5 drugs（DrugBank: 3 drugs),    4 target genes / 6 target pathways ] 

Searched query = "Hutchinson Gilford syndrome", "Hutchinson Gilford progeria syndrome", "HGPS"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03895528August 201929 July 2019Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid LaminopathyA Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid LaminopathyProgeria;HGPSDrug: LonafarnibEiger BioPharmaceuticalsNot recruiting12 MonthsN/AAllPhase 3
2NCT03871972March 5, 20196 May 2019Umbilical Cord Blood Transfusion in Progeria SyndromeSafety and Efficacy of Umbilical Cord Blood Transfusion in Patients With Hutchinson-Gilford Progeria SyndromeHutchinson-Gilford Progeria SyndromeDrug: Umbilical Cord Blood UnitBundang CHA HospitalRecruitingN/AN/AAll2Phase 1/Phase 2Korea, Republic of
3NCT00916747August 200924 June 2019Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children’s HospitalSchering-Plough;Merck Sharp & Dohme Corp.RecruitingN/AN/AAll85Phase 2United States
4NCT00879034March 200924 June 2019A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children’s HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughNot recruitingN/AN/AAll5Phase 2United States
5NCT00425607May 200711 June 2018Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaAn Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: LonafarnibMonica E. KleinmanSchering-PloughNot recruiting1 YearN/AAll29Phase 2United States

Back to top